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Abstract
The myocardial protection allowed great advance in
cardiac surgery, decreasing the mortality and making
more feasible complex surgeries. Latterly the patient
population elected for cardiac procedures has been
changing towards elderly patients with ventricular
function depressed and myocardial hypertrophy. The
myocardial hypertrophy condition represents a great
challenge since the beginning of the cardiac surgery.
Several techniques have been described to protect the
myocardial hypertrophy, however with no satisfactory
results. In this manuscript we present the state of the art
technique of myocardial protection.
Descriptors: Cardioplegic solutions. Hypertrophy, left
ventricular. Hypertrophy, right ventricular. Heart arrest,
induced/methods.
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INTRODUCTION
From the beginning, the cardiac surgery have received
great contributions from scientific and technological
advancements [1], especially after the dramatic
breakthrough generated with the introduction of the
cardiopulmonary bypass (CPB), in 1953, by Gibbon.
Currently, the worldwide groundbreaking development of
ortheses, prostheses, devices, and drugs has allowed a
greater amount of patients to get benefits from cardiac
surgery.
Nevertheless, the adequate protection of the
hypertrophied myocardium during surgical procedure is still
an eternal challenge, because it is known that this heart
already presents ultrastructural changes due to a higher work
overload with low blood requirement, once during the cardiac
surgery procedure is desirable to have as less blood as
possible in the surgical field and the heart should be standstill
and flaccid to be better visualized and to allow the surgical
technique to be carried out. However, the technology
available to maintain the heart adynamic through an adequate
period involves the reduction of blood perfusion. Yet, it is of
common knowledge that the myocardium does not support
long periods of time in such a condition because the cardiac
metabolism is sufficiently high to maintain cellular integrity
and mechanical activity [2].
In this way, throughout cardiac surgery history, the
increasing need of myocardial protection follows its
evolution, imposing challenges to all those who dedicate
themselves to the specialty in developing techniques and
drugs that increase the myocardium tolerance to ischemic
periods, including pharmacologists, physiologists,
pathologists, perfusionists, anesthesiologists, and
surgeons [2], thus contributing to better preserve
myocardial function [3], i.e., to allow interrupting its
electromechanical activity without producing either
structural or functional injury aiming at to facilitate the repair
of existing cardiac lesions.
Among the myocardial protection techniques, we have
aortic clamping [4], hypothermia with ventricular fibrillation
[5], hypothermic crystalloid cardioplegia [6], oxygenated
hypothermic crystalloid cardioplegia [7], intermittent cold
blood cardioplegia [8], intermittent warm blood cardioplegia
[9], cold or warm continuous blood cardioplegia [10],
continuous tepid blood cardioplegia [11], and whole blood
cardioplegia (minicardioplegia) [12].
A great myocardial oxygen consumption variation
occurs during cardiac surgery, which is lowest over the
cardiac standstill induced by cardioplegic solutions and
greatest at the cardiopulmonary bypass exit. Thus, without
an adequate myocardial protection, postoperative morbid-
mortality and the risk of developing ischemic contracture
of the left ventricle, also known as stone heart, or late
myocardial fibrosis are increased. Robinson et al. [13], in
1995, examined the method of myocardial protection used
by North-American surgeons in the United States and they
found that 98% of the cardiovascular surgeons used
cardioplegic standstill and that 60% of them used blood
cardioplegia, 22% crystalloid cardiolegia, and 6%
oxygenated crystalloid cardioplegia. Regarding the
cardioplegic solution delivery pathway, 36% used the
antegrade pathway, 4% the retrograde pathway, and 60%
both pathways. Only 10% of the patients used continuous
warm cardioplegia. Despite the lack of official statistics,
intermittent clamping and crystalloid cardioplegic solutions
are in full vogue in Brazil.
MYOCARDIAL HYPERTROPHY
Myocardial hypertrophy is considered as the most
efficient event among the compensatory mechanisms of
heart diseases when the muscle is exposed to the work
overload depending on extramyocardial disease [14].
Several mechanical and neurohormonal factors act as
myocardial growth factors and change the pattern of protein
synthesis, resulting in a ventricular remodeling. The several
mechanisms in response to the decrease of cardiac
performance, initially adaptive, became developmentally
pernicious [15].
The cardiovascular system is the first of the major
systems to function in the embryo. During the intra-uterine
life it is known that the growth and development of the
heart happens mainly from cell hyperplasia. After birth,
the ventricle walls are affected by the difference of
Resumo
A proteção miocárdica permitiu enorme avanço na moderna
cirurgia cardíaca, reduzindo a mortalidade e permitindo que
operações cada vez mais complexas pudessem ser realizadas.
A alteração na população eleita para procedimentos cirúrgicos
cardiológicos mudou significativamente nas últimas décadas,
com o aumento de pacientes mais idosos, com função
ventricular deprimida e miocárdio hipertrofiado. Essa última
condição, desde os primórdios da cirurgia cardíaca, constituiu-
se em grande desafio. Diversas técnicas de proteção ao
miocárdio hipertrofiado foram descritas, porém com
resultados não alentadores. As características da hipertrofia
miocárdica no adulto com cardiopatia cirúrgica apresentam
particularidades desafiadoras. Nesse artigo, procuramos
atualizar o estado da arte sobre a proteção miocárdica ao
coração hipertrofiado.
Descritores: Soluções cardioplégicas. Hipertrofia
ventricular esquerda. Hipertrofia ventricular direita. Parada
cardíaca induzida, métodos.
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pressure overload between both ventricles, thus occurring
left ventricle hypertrophy (submitted to the highest
pressure overloads) and hypertrophy of 20% of right
ventricle (submitted to  the lowest pressure overloads).
The transition process is completed around the fourth or
fifth weeks after delivery [16]. So, the proliferative capacity
is maintained for a definite period of time in life after birth,
so that cell hypertrophy is the mechanism that gives
continuity to increase of cardiac mass until its complete
development into adult life. The physiologic growth of
the heart occurs in such a harmonic way among its
constituents without impairment to the functional
characteristics of cardiac muscle [17].
The hypertrophy of the myocardium which is under
hemodynamic stress differs from the physiologic
hypertrophy which occurs during its development and does
not correspond to just the increase of normal myocardial
mass [18] due to its low capacity of cell division [19]. From
the histological standpoint, the alteration of the myocardial
architecture involves hypertrophy and loss of myocytes,
fibroblasts hyperplasia, and collagen deposition [20].
The process of ventricular remodeling is influenced by
several factors, such as mechanicals (volumetric or pressure
hemodynamic overload) [21], neurohormonals
(sympatethic, renin-angiotensin, aldosterone, and
endothelin systems), cytokines, oxidative stress, ischemia
or the gene expression factors which will lead to
cardiomyopathies [22].
Among the mechanisms involved in this process, the
major one is the hypertrophy of the myocyte. The
deformation of the membrane and the changes in the
cytoskeleton are detected by the myocardium that
stimulates the expression of myocardial genes and the
changes in the functioning of the ion channels of the
sarcolema and eventually the activation of hypertrophy
mediators such as the calcium-calmodulin system and
calcineurina. It also stimulates the regulation of peptide
growth factor production. There is also a series of
neurohormones and paracrine/autocrine hypertrophy
mediators, including noradrenalin, angiotensin II, endothelin
1, Fibroblast Growth Factor (FGF), TGFâ 1, proinflammatory
cytokines (e.g., TNF-á), and G proteins. By means of signal
transduction proteins (Ras, Gaq, Gas) these mediators
transmit their signs, activating enzymes (protein kinase C
[C-PKC], mitogen-activated protein kinase [MAPK]) which
induce the fetal gene expression, constituting the hallmark
of pathologic hypertrophy which includes gene alterations
involved in the synthesis of contractile proteins,
management of intracellular calcium, natriuretic peptides,
among others. Concurrently with these changes, there is
still fibroblast proliferation and changes in the synthesis
of extracelullar matrix which participate in the genesis of
remodeling [23] (Table 1).
Myocardium presents 70% of myocytes [24] and the
remaining consists of a number of other cell types, vessels,
and interstitial collagen matrix. The balance among these
three compartments contributes to maintain heart shape
and function [25]. Changes in the composition of these
compartments, especially in the collagen – a substance
having relatively high tensile strength to stretching – when
in abnormal quantities in the myocardium, result in
increased passive muscle stiffness and left ventricle
diastolic dysfunction. This phenomenon is mainly observed
when pressure overload is present [25,26]. Current studies
have suggested that muscle stretching imposed by volume
overload favors collagen degradation in a process that
might involves mastocyte degranulation. They also suggest
that volume or pressure overloads cause distinctive
patterns of heart remodeling [26].
MYOCARDIAL PROTECTION
Under normal conditions, cardiac metabolism is
essentially aerobic with great amount of energy synthesis
and consumption. Fat acids are degraded and their
metabolites take part in the following processes: oxidative
phosphorylation, Krebs cycle, and respiratory chain. Fat






















Table 1. Changes found in cardiac remodeling. Adapted from
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Nevertheless, glucose plays an important role in this
metabolism, once several constituents of their degradation
are critical to Krebs cycle adequate functioning [27].
During ischemia, a decline of myocardial metabolism
occurs, which eliminates the energy expenditure for
contractile activity and focus on maintaining cellular
integrity, delaying muscle contraction and relaxation
through two mechanisms: initially, an increase on hydrogen
ions competing for calcium ions based on troponin
activation sites occurs, lentifying the actin-myosin
activation and, consequently, the contraction. Afterwards,
a decrease in high-energy phosphate concentrations
occurs; they are important in process of calcium re-uptake
into sarcoplasmic reticulum, thus jeopardizing the relaxation.
In addition to these mechanisms, severe ischemia induces
to anaerobic metabolism due to the absence of substrate
and oxygen, occurring lactate deposition and consequent
intracellular acidosis. In this way, the main determinants of
post-ischemia ventricular function recovery are the duration
and severity of ischemia, in addition to post-ischemia
reperfusion, which may be present or not, leading to
ischemic contracture of the left ventricle (stone heart) [28].
Based on this knowledge and on the description by
Heyndrickx et al., in 1975, it is observed that the myocardial
depression after ischemia/reperfusion is generated by two
factors: through oxygen-derived free radicals binding
released at the moment of reperfusion and through
increased calcium intracellular concentration (calcium
overload), which occurs during both ischemia and
reperfusion, leading to severe systolic and diastolic
dysfunction which can last minutes or days after cardiac
surgery, bringing up the need to protect the myocardium
during cardioplegia [3].
Currently, “cardioplegia” is defined as the myocardial
protection during a controlled paralysis of the heart, which
represents a mistake, once the exegesis of the term
cardioplegia means “lesion, blow, attack, or wound”, thus
it is correct to use cardioplegic solution. Therefore,
myocardial protection can be achieved through the aid of
cardioplegic solutions added to substrates or elements
allowing the desirable protection [29]. The variety of
strategies which have been widely studied makes this issue
a controversial one.
Myocardial protection defines the set of strategies
targeting to reduce the myocardial ischemia-reperfusion
lesion intensity during cardiac surgery and its
consequences over myocardial function [30] because the
damages to the heart due to an inadequate myocardial
protection, which lead to a low output syndrome, can
prolong the length of hospital stay, resulting in late
myocardial fibrosis [31].
Braile et al. [32], in 1989, emphasized that the cardioplegic
solution should safely promote cardioplegia, create
favorable conditions to a continuous energy production,
and eliminate the deleterious effects of ischemia and
reperfusion. Thus, the composition of a solution should
consist of elements which provide the following: 1. an
immediate paralysis of the heart, avoiding energy depletion;
2. myocardial cooling, reducing metabolic requirement, or
when the myocardium is kept warm, to provide sufficient
flow to maintain aerobic metabolism; 3. substrates for
aerobic or anaerobic metabolism, or both; 4. a buffering
effect against acidosis, avoiding metabolism; 5. stabilization
of the membrane using specific drugs, and 6. avoidance of
edema through hyperosmolarity. All the abovementioned
myocardial protection methods seek to preserve cardiac
function during procedure over the heart with or without
aortic cross-clamping. According to the method or
myocardial conditions, lesions do occur below limit
detection that cannot be perceived or yet reversible lesions
after reperfusion or even caused by reperfusion itself,
leading to permanent myocardial damage. These lesions
should be considered as special to the hearts that have
great energy deficits, as well as to the ischemic,
hypertrophic, dilated, cyanotic, and immature ones. Each
one of them has their own characteristics and they can or
cannot resist to a greater or lower period of ischemia with
different methods of hypothermic or normothermic
cardioplegia, or not, with the addition of amino acids, etc
[32] (Figure 1).
Fig. 1 – Myocardial evolutionary impairment resulting from
ischemia reperfusion or complete occlusion
In brief, we can describe six main techniques types
aiming at myocardial protection; however in current medical
practice, several cardiovascular surgical centers adopt one
type of technique and/or use a combination of different
types.
Thus, we have: 1. intermittent aortic cross-clamping
technique in which occurs, at least over 20 minutes, the
interruption of blood flow in coronary arteries, interposing
periods of reperfusion, taking into consideration that in
this time interval the changes taking place into myocardial
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cells are reversible and that relatively low periods of
ischemia induce an effect over myocardial cells making them
capable of being more tolerant to a second period of
ischemia.
In this way, the cardioprotective effect of the
technique is based on ischemic “preconditioning”. 2. In
the technique of hypothermia with ventricular fibrillation,
aortic cross-clamping induces to fibrillation and
myocardial protection is dependent of metabolic activity
reduction caused by a fall in temperature. 3. A
hypothermic crystalloid cardioplegia consists of infusing
a solution with electrolytic properties slightly
hyperosmolar, producing an electromechanical stopping
of the heart. This solution contains substances aiming
at to reduce the high-energy phosphate consumption
associated with hypothermia followed by a decrease in
metabolic cell activity. 4. Oxygenated hypothermic
crystalloid cardioplegia follows the same principles of
the previous described technique plus oxygen delivery
to supply possible existing metabolic activity. 5.
Hypothermic blood cardioplegia also is based on the
use of hypothermia as a protective factor, but perfusion
consists of blood which presents more physiologic
characteristics to supply a possible cellular activity and
the recovery of energetic phosphate cellular levels which
can be amino acid-fortified (aspartate and glutamate). 6.
Continuous tepid or normothermic cardioplegia is based
on providing nutrients, metabolites, and either amino
acid-fortified oxygen or not continuously aiming at to
maintain cellular metabolic activity, or in certain
situations to promote resuscitation of a myocardium
which has undergone previous injury [2].
Regarding the composition of cardioplegic solution
being either crystalloid or bloody, it is necessary the
presence of an agent which will cause the paralysis of
electromechanical activity of the heart, such as the
following: potassium, magnesium, procaine, chelating
agents, and calcium channel blockers used alone or in
combination. It is important to highlight that potassium
should not exceed 40-mEq/L-level in order to avoid calcium
inflow into the cell and, consequently, oncosis [33].
Among the mechanism of induced cardiac paralysis by
means of cardioplegic solution (hyperpolarization,
depolarization or calcium pump blockers), depolarizing
cardioplegia is the most current used method, but articles
available in the literature already report about the possibility
of using hyperpolarizing solutions that cause more marked
reduction of energetic expenditure [34].
Substrates and oxygen must be added in order to assure
the production of some aerobic metabolism that might be
present during aortic cross-clamping. However, fortified
amino acids, which are mediators of Krebs cycle, can also
be added as quoted before, as well as the own supply of
adenosine triphosphate (ATP) and/or creatine phosphate
(phosphocreatine) [CP] can significantly improve
myocardial protection [35].
Recent studies have shown the close relation of
increased blood lactate levels with severity of tissue oxygen
deficit and decreased oxygen delivery. The occurrence of
such a condition is associated to patients’ high morbidity
and mortality postoperatively. For this reason, it is
necessary, whenever possible, to avoid the appearance of
acidosis or to treat it aggressively [36] using buffering
systems which have the purpose of keeping aerobic
metabolism, functioning of calcium and sodium pumps,
membrane integrity and to buffer acidosis occurring during
myocardial ischemia time. Several types of buffers can be
used, such as sodium bicarbonate [37], phosphate buffer,
imidazole, among others; however, blood is the one
presenting most advantages [38].
Lidocaine is an antiarrhythmic class I-B drug capable of
acting directly into transmembrane conductance of cations,
mainly of sodium, potassium, and calcium. Lidocaine in
association with normothermic hyperkalemic blood
cardioplegia solution provides additional protective effect
to ischemic myocardium during cardiopulmonary bypass
[39]. Also, it can be used to stabilize the cellular membrane,
besides presenting antiarrhythmic features preventing the
appearance of ventricular fibrillation after myocardial
reperfusion [40].
In blood cardioplegia, hiperosmolar solutions help in
the prevention of edemas causing changes into cellular
membrane, as well as the use of calcium chelating [41] which
causes lower cellular edema with the use of minicardioplegia
technique [42].
An adequate composition of a cardioplegic solution
should consist also of free radical scavengers. Ischemic
myocardium produces metabolites that when in contact with
oxygen in the reperfusion phase will give raise to free
radicals which have a definite role in tissue lesion and might
be represented by radical with nitrogen or carbon nucleus,
but mainly by those oxygen-derived that are the superoxide,
hydroxyl ion, and atomic oxygen. The maintenance of
normoxemia (PO2 80-100 mmHg) rather than hyperoxemia
during the beggining of cardiopulmonary bypass
significantly reduced the oxidative lesion and myocardial
dysfunction extension [43].
The studies carried out by McSord & Fridovisch [44]
confirmed the capacity of the superoxide dismutase enzyme
to transform superoxide into a substance less noxious to
the cells, the hydrogen peroxide, which can be removed by
the action of two other enzymes resulting in water as end
product. From this knowledge on, ways were opened to
scavengers’ usage. A temporary interruption of ATP-
dependent calcium (Ca++) pumps leads to increased
intracellular calcium concentrations that during ischemia,
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activates the xanthine oxidase administration route.
Increased intramuscular calcium concentrations during
aortic cross-clamping periods activate the calcium-
dependent proteases that convert xanthine
dehydrogenases into xanthine oxidase. Xanthine oxidase
uses molecular oxygen rather than NAD+ as electron
receptor, thus producing superoxide radical [45].
By understanding the mechanism of free radical
formation during myocardial ischemia, we have two
mechanisms to remove free radicals: 1. Using allopurinol to
reduce the amount of xanthine oxidase, thus preventing
the production of free radicals; or 2. Using components
that act to remove formed free radicals, such as superoxide
dismutase, catalase, peroxidase, manitol, vitamin E, nicotinic
acid, deferoxamine, and others. With continuous
normothermic perfusion, we can avoid ischemia and all
natural scavengers are provided [46], even though the
complete depletion mechanism of free radicals remains
unclear. A study by Luo [47] using aminophylline
(theophylline), a xanthine derivative phosphodiesterase
inhibitor with anti-inflammatory effects suggests that
intracorporeal administration reduces the release of cardiac
Troponin I (cTnI) and activation of neutrophils, improving
cardiac function in patients undergoing cardiopulmonary
bypass for coronary artery bypass grafting.
Regarding temperature (hypothermic, normothermic, or
tepid), it is worth remembering that in 1979, Buckberg [48]
described the controversy about using hypothermia as a
form to protect the myocardium, promoting the reduction
of energy consumption by the tissue, whereas at the same
time occurs a fall in its own production, hampering the
functioning of ATPase-dependent calcium pump, promoting
calcium ion accumulation intracellularly, while the use of
tepid or normothermic cardioplegic solutions (30ºC), once
the adequate substrate for maintenance of cellular
metabolism is provided, reduce the risk of calcium
deposition.
Yet, it must be remembered that oxygen consumption in
a hypothermic myocardium is higher when artificially
stimulated and that the use of hypothermia also requires
hemodilution to overlap severe rheologic problems of
stacks (rouleaux) of red blood cells and capillary obstruction,
which are overcome through normothermia [48].
Lima-Oliveira et al. [49] through experiments showed a
better preservation of myocardial cells, fibroblasts, and
endothelial cells when submitted to a cardiac arrest
protected by low-volume blood cardioplegic solution.
Cressoni et al. [50] showed, experimentally as well, the
superiority of cardiac protection by tepid, continuous
cardioplegic solution in the preservation of myocardial
ultrastructural and structural integrity when compared to
intermittent cold crystalloid cardioplegic solution. Martins
et al. [51] in a similar experiment proved the efficacy of
myocardial protection fostered by retrograde, antegrade,
and continuous blood cardioplegia, which allowed to
further improve the outcomes, mainly those related to
cardiac rhythm.
In a prospective study by Sobrosa et al. [52] involving
15 consecutive patients undergoing cardiac surgery
through continuous retrograde hypothermic blood
cardiolegia with normothermic antegrade induction, they
came to a conclusion that this technique requires less time
to attain asystolia and the improvement of myocardial
protection, but it did not avoid the anaerobic metabolism
during aortic cross-clamping period.
Bothe [53] reported that the myocardial protection degree
provided by the administration of a retrograde cardioplegic
solution varies according to the organ anatomy and that it
is a safe e effective method when associated to an antegrade
cardioplegic solution.
CRYSTALLOID CARDIOPLEGIA
Potassium chloride is used by crystalloid cardioplegic
solutions as agent to promote cardiac arrest [54].
Several basic cellular processes need potassium
participation. Among theses important functions, the
maintenance of intracellular pH, excitability, contractility
of muscle cells, and transmembrane potential, especially
of cardiac cells, are to be highlighted. The distribution
of this cation is predominantly cellular and the muscle
cells are the ones that contribute to a greater storage.
Potassium internal balance represents its motion between
intra- and extracellular spaces; among the factors that
take part in this balance are hormones (insulin,
catecholamines, and aldosterone), acid-base balance,
and plasmatic tonicity; the transmembrane carrier is the
ATPase-dependent Na+/K+ pump [55]. It remains
unknown the accurate potassium concentration required
by a cardioplegic solution; currently, the solutions used
vary from 16 to 25 mEq/L [56].
Magnesium, the second intracellular cation also
presents cardioprotective properties by removing calcium
from the mitochondrium and driving it into sarcoplasmic
reticulum, besides competing with this same ion when it
binds to troponin C and blocks ATP-converting enzyme
action, which reduces myocardial contractility increasing
cardiac reserve. Also it prevents ventricular fibrillation when
administered before aortic cross-clamping [56]. High
magnesium concentrations extracellularly produce
cardioplegia by blocking the calcium channels into the cells.
After prolonged ischemia, when small amounts of
calcium are added to cardioplegic solutions, it seems to
produce a better stability of the cellular membrane,
occurring less injury during reperfusion when calcium
concentration is not in its subnormal level [57].
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Ringer lactate solution, serum, and other solution with
low sodium concentration are used as common transports
of cardioplegic solutions, being the most popular solution,
the St. Thomas’ solution II (Table 1), developed by Hearse
and Bainbridge, in England [57].
Regarding the temperature of cardioplegic solution
administration, several studies from different centers have
reported their experience with the use of both
normothermic and hypothermic solutions. Usually, the
temperature of the solutions attained by checking the
interventricular septum varies from 4º to 7ºC; it is aimed a
temperature between 12º and 18ºC, being that the
temperature reduction depends on both the administered
volume and velocity of the infusion [58].
Crystalloid cardioplegia is usually administrated by
antegrade route through an inflatable pressure bag
connected to a needle or a special catheter inserted into
the aortic root, producing a maximum arterial pressure
between 50 and 60 mmHg [59].
The method is more indicated for short-term
procedures in which the ischemia time é lower than 20
minutes. The main inconveniences of this method are
difficulty in monitoring the amount of administered volume
and the need of having a solution filtered before filling
the plastic bag [59].
BLOOD CARDIOPLEGIA
It was shown that the myocardium, even after an induced
cardiac arrest and hypothermia, presents cellular activity.
The use of blood cardioplegia was then started. It uses the
blood perfusate as a transporter of cardioplegic solution
with the main purpose of delivering oxygen and substrates
and decreasing cellular damage. Blood perfusate is the most
adequate transporter to infusion of cardioplegic agents,
presenting important characteristics to better supply
myocardium and other tissues requirements such as: 1. the
presence of a natural buffer system for maintenance of and
ideal pH; 2. the adequate colloidomsmotic pressure,
decreasing the risk for edema of the myocytes; 3. the
presence of adequate concentrations for maintenance of
cellular function; 4. the capacity of giving oxygen and
withdrawal carbon dioxide; 5. To supply nutrient substrates
to the cells; 6. the presence of free radical natural
scavengers; and 7. Do not produce severe rheologic
changes.
The indicators of the superiority of blood cardioplegia
over the crystalloid cardioplegia can be shown under certain
circumstances, such as the performance of a surgery in the
presence of myocardial hypertrophy; a surgery that requires
a more prolonged cardioplegia time; pediatric
cardiovascular surgery, severe ventricular dysfunction; and
recent history of ischemia.
Regarding the procedure using aortic cross-clamping
with duration inferior to 30-40 minutes, both blood and
crystalloid cardioplegia solutions are equivalent, especially
if crystalloid cardioplegia is oxygenated [60].
The addition of several components in some
compositions to perfusate is what characterizes the blood
cardioplegia, such as electrolytes, sodium bicarbonate,
calcium chelating, vasodilators, and even insulin [61].
Furthermore, a mixture in the following proportion, four
parts of perfusate and one part of crystalloid solution,
which is called “mother” solution, can be presented in
two forms: one is more concentrated to induce
electromechanical arrest of the heart, and another less
concentrated for maintenance of myocardial reperfusion
and cardioplegia (Tables 2 to 5) [62].
In this kind of procedure, cardioplegia can be
administered by an antegrade route, going through
coronary circulation following the normal blood flow
direction, applying a solution directly into the aortic root,
or, selectively in both ostia of the coronary arteries, or,
occasionally, into the coronary grafts. Also, it can be
retrogradely delivered through the coronary sinus ostium
in the right atrium, and it can go through coronary circulation
into the opposite direction, being harvested in the aortic
root [63].
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Regarding to temperature, blood cardioplegia can be
delivered either hypothermically, normothermically, or
tepidly [64].
Hypothermic cardioplegia is not recommended in cases
of ventricular hypertrophy, severe heart failure, significant
myocardial ischemia, and cardiogenic shock, among others.
This technique reduces the expenditure of high-energy
phosphates as well as its production during aortic cross-
clamping period. However, in the abovementioned
circumstances, the myocardium can already present an
important metabolic deficit with a lower production of such
phosphates [65].
The continuous tepid blood cardioplegia, described by
Braile, aims at myocardial protection by delivering the
cardioplegic solution by both intermittent antegrade and
continuous retrograde routes. This kind of cardioplegia
has shown to reduce ischemic and functional damage either
reducing the increase of serum troponins [66,67] or as a
lower increase of lactate [68] and better functional
preservation [69].
The use of such antegrade/retrograde technique,
repeated over each 15 minutes, allowed to further improve
Table 4. “Mother” Solution for blood cardioplegia induction. The added components
and the result in the modified blood, the volumes of the components into
the mother solution, and the solution final concentration ready to be used
are described. ACD is added to reduce blood calcium concentration; insuolin
promotes the entrance of glucose into the cells; papaverine is the vasodilator
agent. Adapted from Braile et al. (1991).
Final concentration
diluted with blood 1:4
340 - 360 mOsm
0.5 - 0.6 mM/l
22 - 24 mEq/l



















































the outcomes, especially regarding
cardiac rhythm, once the heart takes
over sinusal rhythm with an adequate
frequency just after the aortic cross-
clamping interruption. The explanation
is better understood through a better
cardioplegic solution distribution,
especially for regions of interventricular
septum, right atrium and ventricle,
including the conducting system of
heart [70,71].
CONCLUSION
The concern with myocardial
protection will always be one of the
most important points, from the moment
to decide to submit the patient to
cardiac surgery on, always keeping in
mind that such procedure aims at
improving the patient’s quality of life,
especially of those who already have
some degree of deficiency from cardiac
muscle work.
Recent studies could have
evidenced a cellular cardiac metabolic
activity during the induced cardiac
arrest with cardioplegic solution, thus
proving the need to adequately supply
nutrients and oxygen.
Yet supplying adequately
substrates, there is a production of free radicals, changes
in transmembrane potentials, and possibility of cellular
edema, being necessary to add to the cardioplegic solution
not only nutrients but also free radical scavengers and
membrane stabilizers , some of them with antiarrhythmic
properties.
The studies have also shown the superiority of blood
cardioplegia over the crystalloid cardioplegia, especially
by its more physiologic characteristics.
Regarding the temperature, the route of cardiac arrest
and delivery of cardioplegic solution is still at the surgeon
discretion, including his/her practice and expertise, always
seeking for the best.
And, at last, regarding myocardial protection to a
hypertrophied heart, experimental studies have shown the
superiority of tepid blood cardioplegia in relation to
hypothermic crystalloid, but this pathological entity,
increasingly supervening in the population, constitutes an
eternal challenge for cardiac surgeons, besides the
intrinsically patient’s characteristics. However, we should
always have in mind that the state-of-the-art was not
achieved yet.
CRESSONI, ES ET AL - Myocardial protection to the hypertrophied
heart: the eternal challenge
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